Per London predicts EVOX will initiate clinical trials in Huntington's disease patients (stage 2) in the second half of 2027.
“We're going into the clinic next year, second half of next year. And so we're looking to go into Huntington's patients in stage two”
→ Read the source episode
Our resolution criterion
disputableEVOX announces or publicly confirms initiation of clinical trial in Huntington's disease patients in stage 2 by end of Q4 2027
More from Beyond Biotech
Stuart Medina predicts Bio Spain 2026 Talent Day will exceed the 125 job interviews arranged in the previous year
Per London predicts EVOX will generate initial clinical data from Huntington's trials in 2028-2029.
Per Lundin predicts EVOX's Huntington's gene editing therapy will be in routine clinical use within 10 years from 2026.
Narissa Kreyer predicts Alterna will demonstrate AP-003 establishes functional protein and impacts biomarkers/efficacy endpoints in humans within five years
Per London expresses hope that EVOX's Huntington's therapy will be routinely used clinically within 10 years (by 2036).
Narissa Kreyer predicts Alterna will conduct a clinical study in adult PKU patients demonstrating AP-003 protein generation and biomarker reduction
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.